The U.S. Food and Drug Administration has approved an Abbreviated New Drug Application (ANDA) numbered ANDA076850 for a terconazole vaginal suppository.
The product, marketed by Fougera Pharms, is a 80 mg terconazole suppository intended for vaginal administration. The submission was an original (ORIG) filing and received approval on July 12, 2006.
FDA records indicate the product’s marketing status is listed as discontinued.
규제 업데이트2026년 9월 22일•1분 읽기
FDA Approves ANDA076850 for Terconazole Vaginal Suppository
FDA granted approval (ANDA076850) for Fougera Pharms' terconazole 80 mg vaginal suppository, now listed as discontinued.
PharmaCountry 팀이 정리했습니다 · 출처: FDA.gov
평점
(0)
(0)
(0)
(0)
(0)
평가 남기기